Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

A Sen­ate bill that would black­list Chi­nese biotech com­pa­nies like WuXi AppTec from do­ing busi­ness in the US may not see a vote un­til af­ter the elec­tion, if ever. But if it does, the Con­gres­sion­al Bud­get Of­fice on Tues­day said the bill won’t in­crease the fed­er­al debt.

While biotech and drug com­pa­nies have re­peat­ed­ly out­lined the dis­rup­tion the leg­is­la­tion would cause, the CBO’s de­ter­mi­na­tion re­moves an ob­sta­cle in a Con­gress where Re­pub­li­cans rou­tine­ly block pro­pos­als that aren’t bud­get-neu­tral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER